K-RAS Mutant Pancreatic Tumors Show Higher Sensitivity to MEK than to PI3K Inhibition In Vivo

Irmgard Hofmann; Andreas Weiss; Gaelle Elain; Maria Schwaederle; Dario Sterker; Vincent Romanet; Tobias Schmelzle; Albert Lai; Saskia M. Brachmann; Mohamed Bentires-Alj; Thomas M. Roberts; William R. Sellers; Francesco Hofmann; Sauveur-Michel Maira

doi:10.1371/journal.pone.0044146

Loading metrics

Open Access

Peer-reviewed

Research Article

K-RAS Mutant Pancreatic Tumors Show Higher Sensitivity to MEK than to PI3K Inhibition In Vivo

Irmgard Hofmann ,

* E-mail: irmgard.hofmann@novartis.com

Affiliation Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel, Switzerland
⨯
Andreas Weiss,

Affiliation Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel, Switzerland
⨯
Gaelle Elain,

Affiliation Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel, Switzerland
⨯
Maria Schwaederle,

Affiliation Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel, Switzerland
⨯
Dario Sterker,

Affiliation Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel, Switzerland
⨯
Vincent Romanet,

Affiliation Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel, Switzerland
⨯
Tobias Schmelzle,

Affiliation Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel, Switzerland
⨯
Albert Lai,

Affiliation Novartis Institutes for Biomedical Research, Oncology Disease Area, Emeryville, California, United States of America
⨯
Saskia M. Brachmann,

Affiliation Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel, Switzerland
⨯
Mohamed Bentires-Alj,

Affiliation Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland
⨯
Thomas M. Roberts,

Affiliation Dana Farber Cancer Institute, Boston, Massachusetts, United States of America
⨯
William R. Sellers,

Affiliation Novartis Institutes for Biomedical Research, Oncology Disease Area, Cambridge, Massachusetts, United States of America
⨯
Francesco Hofmann,

Affiliation Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel, Switzerland
⨯
Sauveur-Michel Maira

Affiliation Novartis Institutes for Biomedical Research, Oncology Disease Area, Basel, Switzerland
⨯

K-RAS Mutant Pancreatic Tumors Show Higher Sensitivity to MEK than to PI3K Inhibition In Vivo

Irmgard Hofmann,
Andreas Weiss,
Gaelle Elain,
Maria Schwaederle,
Dario Sterker,
Vincent Romanet,
Tobias Schmelzle,
Albert Lai,
Saskia M. Brachmann,
Mohamed Bentires-Alj

Published: August 31, 2012
https://doi.org/10.1371/journal.pone.0044146

Reader Comments (0)

Post a new comment on this article

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

Pancreatic cancer
Is the Subject Area "Pancreatic cancer" applicable to this article?

Thanks for your feedback.
Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
Lung and intrathoracic tumors
Is the Subject Area "Lung and intrathoracic tumors" applicable to this article?

Thanks for your feedback.
Breast cancer
Is the Subject Area "Breast cancer" applicable to this article?

Thanks for your feedback.
Colorectal cancer
Is the Subject Area "Colorectal cancer" applicable to this article?

Thanks for your feedback.
MAPK signaling cascades
Is the Subject Area "MAPK signaling cascades" applicable to this article?

Thanks for your feedback.
Cancers and neoplasms
Is the Subject Area "Cancers and neoplasms" applicable to this article?

Thanks for your feedback.
Malignant tumors
Is the Subject Area "Malignant tumors" applicable to this article?

Thanks for your feedback.